{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T20:01:12Z","timestamp":1781812872159,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Acute graft versus host disease (aGVHD) is a common complication of stem cell transplant (SCT), with skin involvement being most common. Severe presentations of skin aGVHD involving rapid progression of rash to bullae formation and mucosal involvement are rare. There are reports of patients with skin aGVHD that present with clinical characteristics mimicking toxic epidermal necrolysis (TEN), suggesting a possible overlap between the two. Management and outcomes of pediatric patients with this overlapping, severe presentation have rarely been described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>This report describes an 11-year-old boy with refractory T-cell acute lymphoblastic leukemia who received peripheral blood SCT from a matched unrelated donor. Day 26 post-SCT, he developed a maculopapular facial rash, which progressed to the development of vesicles coalescing into bullae involving his conjunctiva, face, oral mucosa, and genital mucosa. Initially, systemic steroid monotherapy was initiated, but with rapid rash progression and mucosal involvement, intravenous immunoglobulin (IVIg) 2 g\/kg divided over 5 days was added as management for suspected TEN-like aGVHD based on clinical findings. Ruxolitinib was subsequently started as adjunctive management for aGVHD. His skin findings continued to improve with near total resolution by day 49 post-SCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We report a unique case of TEN-like aGVHD with rapid progression to &amp;gt;30% body surface area involvement including bullae formation and detachment of epidermis. There have been few case reports of similar presentations, most with poor outcomes. We aim to supplement the literature available by reporting our successful management with steroids, IVIg, and ruxolitinib, which resulted in early resolution of symptoms in a pediatric patient.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1452245","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T06:57:38Z","timestamp":1737615458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case report: Toxic epidermal necrolysis as a unique presentation of acute graft versus host disease in a pediatric patient"],"prefix":"10.3389","volume":"15","author":[{"given":"Elizabeth","family":"Marlowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April L.","family":"Rahrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Dinora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Skiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahvish Q.","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2009.24.4.287","article-title":"Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation","volume":"24","author":"Imamura","year":"2009","journal-title":"Korean J Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/tjh.galenos.2019.2019.0157","article-title":"Acute graft-versus-host disease: A brief review","volume":"37","author":"Aladag","year":"2020","journal-title":"Turk J Haematol"},{"key":"B4","first-page":"21","article-title":"The biology of graft-versus-host reactions","volume":"62","author":"Billingham","year":"1966","journal-title":"Harvey Lect"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.187","article-title":"Risk and prognostic factors for acute GVHD based on NIH consensus criteria","volume":"48","author":"Lee","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(00)00677-9","article-title":"Acute graft-vs-host disease: pathobiology and management","volume":"29","author":"Goker","year":"2001","journal-title":"Exp Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.1992383","article-title":"New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD)","volume":"25","author":"Choe","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.med.54.101601.152339","article-title":"Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant","volume":"54","author":"Vogelsang","year":"2003","journal-title":"Annu Rev Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.8.1464.1464","article-title":"A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment","volume":"76","author":"Martin","year":"1990","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT\u2013NIH\u2013CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplantation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines10092105","article-title":"A review of the systemic treatment of stevens-johnson syndrome and toxic epidermal necrolysis","volume":"10","author":"Chang","year":"2022","journal-title":"Biomedicines"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in stevens-johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.007","article-title":"Methylprednisolone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers","volume":"69","author":"Hirahara","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.2014.54.issue-1","article-title":"Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies","volume":"54","author":"Barron","year":"2015","journal-title":"Int J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"B18","article-title":"The use of intravenous high-dose immunoglobulins (IGIV) in a case of Stevens-Johnson syndrome","volume":"14","author":"Amato","year":"1992","journal-title":"Pediatr Med Chir"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.113080","article-title":"Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases","volume":"79","author":"Jagadeesan","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0167120","DOI":"10.1371\/journal.pone.0167120","article-title":"The effect of intravenous immunoglobulin combined with corticosteroid on the progression of stevens-johnson syndrome and toxic epidermal necrolysis: A meta-analysis","volume":"11","author":"Ye","year":"2016","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.917782","article-title":"Diagnostic and therapeutic dilemma in Stevens-Johnson syndrome-like acute graft-versus-host disease after liver transplantation: A case report","volume":"13","author":"Hung","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/BCR.0000000000000040","article-title":"Extensive toxic epidermal necrolysis versus acute graft versus host disease after allogenic hematopoietic stem-cell transplantation: challenges in diagnosis and management","volume":"35","author":"Macedo","year":"2014","journal-title":"J Burn Care Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03326.x","article-title":"Stage IV cutaneous acute graft-versus-host disease. Clinical and histological study of 15 cases","volume":"23","author":"Goiriz","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2012.00746.x","article-title":"Graft-versus-host disease or toxic epidermal necrolysis: diagnostic dilemma after liver transplantation","volume":"14","author":"Jeanmonod","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15069","article-title":"Toxic epidermal necrolysis-like acute graft-versus-host disease in pediatric bone marrow transplant patients: Case series and review of the literature","volume":"39","author":"Sheu Song","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17310","article-title":"Toxic epidermal necrolysis-like acute cutaneous graft-versus-host disease in a stem cell recipient - a diagnostic dilemma","volume":"35","author":"Klein","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_889_19","article-title":"Nikolsky\u2019s sign: A pathognomic boon","volume":"9","author":"Maity","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jaad.2022.10.035","article-title":"Acute graft-versus-host disease presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study","volume":"88","author":"Hung","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08061-0","article-title":"Spatial proteomics identifies JAKi as treatment for a lethal skin disease","volume":"635","author":"Nordmann","year":"2024","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1452245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T06:57:40Z","timestamp":1737615460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1452245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2024.1452245"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1452245","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"article-number":"1452245"}}